Immatics (IMTX) Q2 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$0.53

Estimate

-$0.48

Surprise

-12.1%

Score today

5.8/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Immatics (IMTX) reported a wider loss than forecast — adjusted EPS of -$0.53 against the -$0.48 estimate (a 12.1% shortfall).

• Immatics Q2 EPS $(0.53) Misses $(0.43) Estimate, Sales $10.630M Miss $14.590M Estimate — benzinga, 2026-08-18

TrendMatrix currently rates IMTX Sell at 5.8/10; no pre/post engine snapshot brackets this report.

1 of the last 4 quarters beat the estimate; this quarter's -12.1% surprise compares with a +2.1% four-quarter average. Next scheduled report: 2026-11-17.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$7.14

Price target

$15.01

Stop

$6.64

Upside to target

+110.2%

Reward-to-risk

8.6:1

Model outputs from TrendMatrix’s engine as of 2026-10-16 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$1.09B

P/E (fwd)

-3.5

52-week range

$6.73–$12.41

Off 52-week high

42.5%

RSI (14)

30

Volume vs avg

1.64×

Score today

5.8/10